Document is current
Any future updates will be listed below
-
Authors
Gurshaney, Sanjeev
Morales-Alvarez, Anamaria https://orcid.org/0000-0002-9906-7058
Ezhakunnel, Kevin https://orcid.org/0000-0002-6171-474X
Manalo, Andrew
Huynh, Thien-Huong
Abe, Jun-Ichi https://orcid.org/0000-0001-7439-7774
Le, Nhat-Tu
Weiskopf, Daniela
Sette, Alessandro https://orcid.org/0000-0001-7013-2250
Lupu, Daniel S.
Gardell, Stephen J.
Nguyen, Hung https://orcid.org/0000-0001-9416-5137
-
Funding
Funding for this research was provided by:
UCF | College of Medicine, University of Central Florida (7015)
- License Information
-
More Information
Article History
Received: 6 December 2021
Accepted: 20 March 2023
First Online: 7 April 2023
Competing interests
: UCF has filed for a patent of COVID-19 diagnostic assay based on current work. A.S. is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group, and Guggenheim. L.J.I. has filed for patent protection for various aspects of T-cell epitope and vaccine design work.
: This study was approved by the IRB committee of AdventHealth hospital and UCF under protocols #1668907 and #1590483.
